Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Pteridines

Official Journal of the International Society of Pteridinology

Editor-in-Chief: Fuchs, Dietmar

1 Issue per year


IMPACT FACTOR 2017: 0.586

CiteScore 2017: 0.53

SCImago Journal Rank (SJR) 2017: 0.179
Source Normalized Impact per Paper (SNIP) 2017: 0.176

ICV 2017: 151.21

Open Access
Online
ISSN
2195-4720
See all formats and pricing
More options …
Volume 24, Issue 1

Issues

Immune activation and inflammation in patients with cardiovascular disease are associated with elevated phenylalanine-to-tyrosine ratios

Harald Mangge
  • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Wolfgang J. Schnedl / Sebastian Schröcksnadel / Simon Geisler / Christian Murr / Dietmar Fuchs
Published Online: 2013-04-26 | DOI: https://doi.org/10.1515/pterid-2013-0002

Abstract

Higher serum neopterin concentrations and kynurenine-to-tryptophan (Kyn/Trp) ratios are associated with increased mortality in patients with coronary artery disease (CAD). Preferentially, Th1-type cytokine interferon-γ stimulates tryptophan breakdown and neopterin production by GTP cyclohydrolase I (GCH-I) in parallel in monocyte-derived macrophages and dendritic cells. In other cells, activation of GCH-I leads to the formation of 5,6,7,8-tetrahydrobiopterin (BH4), the necessary cofactor of amino acid hydroxylases such as phenylalanine 4-hydroxylase (PAH) and nitric oxide synthases. In 31 CAD patients (70.3±9.9 years; 21 males, 10 females), we determined serum concentrations of phenylalanine, tyrosine, and Kyn/Trp by HPLC, neopterin by ELISA, and nitrite by the colorimetric Griess assay. The phenylalanine-to-tyrosine ratio (Phe/Tyr) served as an estimate of PAH enzyme activity. Elevated Phe/Tyr concentrations were detected in a subgroup of CAD patients and correlated with Kyn/Trp (r=0.396, p<0.05) and neopterin (r=0.354, p<0.05) and inversely with nitrite (r=–0.371, p<0.05) concentrations. Higher Phe/Tyr in patients is associated with immune activation and indicates subnormal PAH activity that might be involved in the precipitation of neuropsychiatric symptoms in CAD patients.

Keywords: coronary artery disease; neopterin; phenylalanine; phenylalanine hydroxylase; tetrahydrobiopterin

Introduction

The development and progression of coronary artery disease (CAD) is closely associated with signs of immune activation and inflammation. Thereby, activated macrophages and the proinflammatory cytokine interferon-γ (IFN-γ) appear to play a major role [1]. In monocyte-derived macrophages and dendritic cells, IFN-γ triggers GTP cyclohydrolase I, the key enzyme for the biosynthesis of pteridine derivatives such as neopterin and 5,6,7,8-tetrahydrobioptein (BH4) [2, 3]. Accordingly, an elevated neopterin concentration is a sensitive indicator of Th1-type immune response. In parallel to GTP cyclohydrolase I, IFN-γ also stimulates tryptophan breakdown rate by the enzyme indoleamine 2,3-dioxygenase [3, 4]. The close association found between elevated serum neopterin concentrations and a higher tryptophan breakdown index, the kynurenine-to-tryptophan ratio (Kyn/Trp), in CAD patients underlines this relationship [5]. Moreover, a strong prognostic value for cardiovascular and total mortality is well documented for neopterin and Kyn/Trp concentrations [6–10].

It has been indicated that inflammation and immune activation also disturb the conversion of phenylalanine to tyrosine: in patients suffering from clinical conditions, which is in agreement with immune activation and inflammation such as sepsis, cancer, or HIV-1 infection, but also in the healthy elderly, increased phenylalanine and an increased phenylalanine-to-tyrosine (Phe/Tyr) concentrations have been described correlating with markers of immune activation such as neopterin [11–14].

In this pilot study, we determined serum concentrations of phenylalanine and tyrosine as well as the Phe/Tyr ratios in CAD patients and compared results to concentrations of neopterin, Kyn/Trp, and nitrite.

Patients and methods

Thirty-one patients (21 males, 10 females), aged 70.0±11.9 years (males, 67.7±13.2 years; females, 74.9±6.7 years), with coronary heart disease confirmed by coronary angiography were included in this study. Patients were recruited from the Practice for General Internal Medicine (Dr. W.J. Schnedl, Bruck/Mur, Austria). Ten patients (4 females, 6 males) had coronary artery stenosis with no intervention, 13 patients (3 females, 10 males) were after stent implantation, and eight patients (3 females, 5 males) were after coronary artery bypass graft surgery. Patients received several medications, mainly statins, antihypertensive and antidiabetic drugs according to current treatment guidelines for coronary heart disease [15]. Sixteen patients (52%) presented with a body mass index (BMI) >30 kg/m2, and 15 patients (48%) had a systolic blood pressure >135 mm Hg. Twenty patients suffered from diabetes mellitus type 2 with blood fasting glucose concentrations >100 mg/dL.

Concentrations of phenylalanine, tyrosine, tryptophan, and kynurenine were assayed by HPLC as described earlier [16, 17]. Phe/Tyr was calculated to estimate activity of enzyme phenylalanine hydroxylase (PAH) [11, 18, 19], and Kyn/Trp indicated the rate of tryptophan breakdown [5]. Neopterin concentrations were quantified by commercially available ELISA (BRAHMS-Thermo Fisher, Hennigsdorf, Germany). Nitrite concentrations were determined colorimetrically utilizing the Griess reaction [20]. Other standard laboratory markers such as total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol, as well as triglycerides, glucose, and urate concentrations were measured by routine laboratory diagnostic methods.

The study was in accordance with the Helsinki declaration, and all individuals included gave informed consent that results of additional measurements were solely used for scientific purposes in a blinded manner. All laboratory measurements were performed in a blinded manner without knowledge about the diagnoses and disease status of patients.

Concentrations of analytes were given as mean values±SD. For comparison of mean values of grouped data, Student’s test was applied, and associations between parameters were tested by linear correlation analysis. The Statistical Package for the Social Sciences (PASW Statistics 18, Chicago, IL, USA) was used. A p-value <0.05 was considered to indicate statistically significant differences and correlations.

Results

Concentrations of markers are shown in Table 1. There was no significant influence of gender. Twenty patients (47%) presented with phenylalanine concentrations above the upper limit of normal in middle-aged healthy individuals which is 75 μmol/L [21], 12 patients (28%) had Phe/Tyr >1.15, the cut-off value previously considered to be useful [22]. Phe/Tyr correlated with age (r=0.391), with neopterin concentrations (r=0.354) and with Kyn/Trp (r=0.396, all p<0.05; Figure 1). Further, neopterin concentrations correlated with Kyn/Trp (r=0.614, p<0.001; Figure 2) and inversely with nitrite concentrations (r=–0.371, p<0.05).

Table 1

Results of laboratory measurements in 31 patients suffering from cardiovascular disease and split into two groups by gender (mean values±SD are shown; all differences between males and females are non-significant).

Associations of serum phenylalanine-to-tyrosine ratios (Phe/Tyr) with neopterin concentrations (r=0.354, p<0.05; upper graph) and with kynurenine-to-tryptophan ratios (Kyn/Trp) (r=0.396, p<0.05; lower graph) in 31 patients with coronary artery disease (open circles, 10 females; filled circles, 21 males).
Figure 1

Associations of serum phenylalanine-to-tyrosine ratios (Phe/Tyr) with neopterin concentrations (r=0.354, p<0.05; upper graph) and with kynurenine-to-tryptophan ratios (Kyn/Trp) (r=0.396, p<0.05; lower graph) in 31 patients with coronary artery disease (open circles, 10 females; filled circles, 21 males).

Association between serum kynurenine-to-tryptophan ratios (Kyn/Trp) and neopterin concentrations (r=0.617, p<0.01) in 31 patients with coronary artery disease (open circles, 10 females; filled circles, 21 males).
Figure 2

Association between serum kynurenine-to-tryptophan ratios (Kyn/Trp) and neopterin concentrations (r=0.617, p<0.01) in 31 patients with coronary artery disease (open circles, 10 females; filled circles, 21 males).

When only the subgroup of males (n=21) was considered, the associations between marker concentrations were similar: Phe/Tyr correlated with age (r=0.426, p<0.05), neopterin concentrations (r=0.518, p<0.02), and Kyn/Trp (r=0.617, p<0.01). Moreover, neopterin concentrations correlated with Kyn/Trp (r=0.826, p<0.001) and inversely with nitrite concentrations (r=–0.490, p<0.07). There were no significant relationships between absolute phenylalanine concentrations and any concentrations of the analytes.

Discussion

In patients with CAD, we report associations between higher Phe/Tyr and higher neopterin and Kyn/Trp concentrations, both the latter variables indicating immune activation. The positive correlation found between neopterin and Kyn/Trp is in agreement with their close immunobiological background, namely, Th1-type immune activation, and their association with higher Phe/Tyr thus indicates that a disturbed PAH functional activity may be related to immune activation. Similar positive relationships between Phe/Tyr and immune activation markers have been described earlier in patients suffering from different diseases in which immune activation plays a major role and is associated with adverse outcome such as ovarian carcinoma, HIV-1 infection, and also in patients after trauma and with sepsis [12, 13, 17]. Taking all results together, it seems fairly reasonable that immune activation leads to the increase of Phe/Tyr in CAD patients.

According to the literature, alterations of phenylalanine and of Phe/Tyr could be involved in a wide spectrum of neuropsychiatric abnormalities in patients [11, 14, 23, 24]. Previously in healthy elderly individuals, increased phenylalanine concentrations and increased Phe/Tyr have been found to be correlated with scores for depressive symptoms such as Montgomery-Asberg Depression Rating Scale (MADRS) or with a fatigue inventory or with a neurotoxicity rating scale (NRS) [14]. Additionally, in patients with HCV infection under treatment with IFN-α a significant increase of blood Phe/Tyr and phenylalanine concentrations was reported [25, 26]. Moreover, in the same patients, an association between disturbed phenylalanine metabolism and low dopamine concentrations in the cerebrospinal fluid was evident and disturbances are correlated with fatigue scores [24]. Unfortunately, neuropsychiatric test results were not available from our patients, and further studies are to be conducted to address this relationship in CAD patients.

The increase of Phe/Tyr may be due to impaired function of PAH that could result from BH4 deficiency. However, during inflammatory processes involving increased formation of IFN-γ, GTP cyclohydrolase I is induced and primarily leads to the formation of BH4. Only in humans and primates, but not in cells from other species, significant production of neopterin is detected in cells of the monocytes-macrophages lineage, whereas in other cells and in other species only the biosynthesis of BH4 is of relevance [27]. BH4, the necessary cofactor of several monooxygenases of amino acids including PAH [28], nitric oxide (NO) synthases (NOS) [29] and of glyceryl ether monoxygenase [30], is released in increased amounts from, for example, endothelial cells. Consequently, production of vasodilatory NO increases during acute immune activation processes and blood pressure falls. However, in CAD patients a paradox seems to exist because patients show signs of vasoconstriction despite their proinflammatory status [31, 32]. Therefore, supplementation of patients with BH4 is one current strategy to treat increased blood pressure, however, thus far with only very limited success [32]. Although the direct measurement of BH4 in the blood of patients is technically feasible [33], preanalytical requirements are complex and thus not easily applicable in clinical studies. Instead, measurement of phenylalanine and tyrosine and calculating Phe/Tyr may overcome this limitation and can serve as a surrogate of BH4. The measurement of Phe/Tyr could lead to a better understanding of BH4 biochemistry in patients, because any deficiency of BH4 should cause an increase of Phe/Tyr also in patients with normal genetic background of PAH [11].

When BH4 availability is disturbed, it should also affect other BH4-dependent enzymatic pathways such as NOS activity for which cofactor BH4 is an important regulator of functional activity and is required to maintain enzymatic coupling of L-arginine oxidation to produce NO [31, 32]. Loss or oxidation of BH4 to 7,8-dihydrobiopterin (BH2) is associated with NOS uncoupling that results in the production of vasoconstrictor superoxide anion (O2, hyperoxide anion) at the expense of vasodilatory NO [32]. Thus, BH4 deficiency not only impairs PAH activity and increases Phe/Tyr but at the same time diminishes NO production. Our study shows some weak inverse association between Phe/Tyr and nitrite concentrations which also points towards BH4 deficiency. It should be noted that nitrite concentrations can only serve as a rough estimate of NO production rates, but at least our conclusion is further supported by the inverse association between nitrite and neopterin concentrations and Kyn/Trp. Also, ample evidence already exists which indicates that NO production is impaired in CAD patients even though immune activation and IFN-γ production would induce inducible NOS (iNOS) gene expression [34]. This conclusion is in line with increased blood pressure often seen in patients, most probably due to vasoconstriction rather than vasodilation. Thus, our findings may help to explain the existing paradox that particular chronic inflammatory conditions such as CAD are in line with high rather than low blood pressure.

In summary, our study provides preliminary data that patients with CAD and higher serum neopterin and Kyn/Trp levels may exhibit higher Phe/Tyr ratios; a finding which is most probably due to impaired PAH activity. However, such results need to be confirmed by a larger sized investigation and also a comparison of CAD patients with healthy controls of the same age. Still, our data indicate disturbed phenylalanine metabolism in CAD patients, which could possibly be associated with neuropsychiatric disturbances because phenylalanine metabolism is closely related to neurotransmitter biosynthesis. Thus, further studies may shed more light on the background of neuropsychiatric disturbances in CAD patients. Finally, in the absence of an easy routine assessment of BH4 concentrations in patients, measurements of Phe/Tyr may allow some indirect information on the availability of BH4 and the functional activity of BH4-dependent enzymes including NOS.

The authors thank Mrs. Maria Pfurtscheller and Mr. Thomas Nuener for excellent technical assistance.

References

  • 1.

    Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317–25.Web of ScienceGoogle Scholar

  • 2.

    Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-associated production of neopterin – release from macrophages primarily under control of interferon-γ. J Exp Med 1984;160:310–6.Google Scholar

  • 3.

    Wirleitner B, Reider D, Ebner S, Böck G, Widner B, Jaeger M, et al. Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 2002;2:1148–53.Google Scholar

  • 4.

    Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1 and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-γ, 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 1990;265:3189–92.Google Scholar

  • 5.

    Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82–90.Google Scholar

  • 6.

    Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003;33:550–4.PubMedCrossrefGoogle Scholar

  • 7.

    Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimäki T, Kähönen M, et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008;68:767–70.Web of ScienceGoogle Scholar

  • 8.

    Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra Sanchez L, Kaski JC. The role of neopterin in atherogenesis and cardiovascular risk stratification. Curr Med Chem 2009;16: 4644–53.CrossrefGoogle Scholar

  • 9.

    Grammer TB, Fuchs D, Böhm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 2009;55:115–46.Google Scholar

  • 10.

    Pedersen ER, Midttun Ø, Ueland PM, Schartum-Hansen H, Seifert R, Igland J, et al. Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011;31:698–704.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 11.

    Neurauter G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008;9:622–7.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 12.

    Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlates to neopterin concentrations. Amino Acids 2008;35:303–7.Web of ScienceGoogle Scholar

  • 13.

    Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 2010;24:403–8.Web of SciencePubMedGoogle Scholar

  • 14.

    Capuron L, Schroecksnadel S, Féart C, Aubert A, Higueret D, Barberger-Gateau P, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011;70:175–82.Web of ScienceGoogle Scholar

  • 15.

    Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110(Suppl 1):3A–14A.Google Scholar

  • 16.

    Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997;43:2424–6.Google Scholar

  • 17.

    Neurauter G, Grahmann AV, Klieber M, Zeimet A, Ledochowski M, Sperner-Unterweger B, et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett 2008;272:141–7.Web of ScienceGoogle Scholar

  • 18.

    Rosenblatt D, Scriver CR. Heterogeneity in genetic control of phenylalanine metabolism in man. Nature 1968;218:677–8.Google Scholar

  • 19.

    Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA. Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterin-dependent hydroxylation. Acta Psychiatr Scand 1994;90:10–3.Google Scholar

  • 20.

    Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. Adaptation of the Griess reaction for detection of nitrite in human plasma. Free Radic Res 2004;38:1235–40.Google Scholar

  • 21.

    Shih VE. Amino acid analysis. In: Blau N, Duran M, Blaskovic ME, Gibson KM, editors. Physician’s guide to the laboratory diagnosis of metabolic diseases, 2nd ed. Berlin: Springer, 2003:11–26.Google Scholar

  • 22.

    Scholl-Bürgi S, Schroecksnadel S, Jenny M, Karall D, Fuchs D. Chronic immune stimulation may cause moderate impairment of phenylalanine 4-hydroxylase. Pteridines 2011;22:120–5.Google Scholar

  • 23.

    Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137–62.Web of ScienceGoogle Scholar

  • 24.

    Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, et al. Tyrosine metabolism during interferon-α administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 2012;pii:S0889-1591(12)00472-2.Web of ScienceGoogle Scholar

  • 25.

    Van Gool AR, Fekkes D, Kruit WH, Mulder PG, Ten Hagen TL, Bannink M, et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-α in high-risk melanoma patients. Psychiatry Res 2003;119:125–32.Google Scholar

  • 26.

    Zoller H, Schloegl A, Schroecksnadel S, Vogel W, Fuchs D. Influence of interferon-α therapy on phenylalanine hydroxylase activity in patients with HCV infection. J Interferon Cytokine Res 2012;32:216–20.CrossrefGoogle Scholar

  • 27.

    Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metabol 2002;3: 175–87.CrossrefGoogle Scholar

  • 28.

    Kaufman S. Hepatic phenylalanine hydroxylase and PKU. UCLA Forum Med Sci 1975;18:445–58.PubMedGoogle Scholar

  • 29.

    Fitzpatrick PF. The tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem 1999;68:355–81.Google Scholar

  • 30.

    Watschinger K, Keller MA, Golderer G, Hermann M, Maglione M, Sarg B, et al. Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. Proc Natl Acad Sci USA 2010;107:13672–7.Web of ScienceGoogle Scholar

  • 31.

    Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide 2011;25:81–8.CrossrefWeb of SciencePubMedGoogle Scholar

  • 32.

    Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012;125:1356–66.Web of ScienceGoogle Scholar

  • 33.

    Biondi R, Ambrosio G, De Pascali F, Tritto I, Capodicasa E, Druhan LJ, et al. HPLC analysis of tetrahydrobiopterin and its pteridine derivatives using sequential electrochemical and fluorimetric detection: application to tetrahydrobiopterin autoxidation and chemical oxidation. Arch Biochem Biophys 2012;520:7–16.Web of ScienceGoogle Scholar

  • 34.

    Kwon NS, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989;264:20496–501.Google Scholar

About the article

Corresponding author: Dietmar Fuchs, Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innrain 80, 6020 Innsbruck, Austria, Fax: +43-512-9003-73330


Received: 2013-02-07

Accepted: 2013-03-22

Published Online: 2013-04-26

Published in Print: 2013-06-01


Citation Information: Pteridines, Volume 24, Issue 1, Pages 51–55, ISSN (Online) 2195-4720, ISSN (Print) 0933-4807, DOI: https://doi.org/10.1515/pterid-2013-0002.

Export Citation

©2013 by Walter de Gruyter Berlin Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Vanessa Valdiglesias, Diego Marcos-Pérez, Maria Lorenzi, Graziano Onder, Johanna M. Gostner, Barbara Strasser, Dietmar Fuchs, and Stefano Bonassi
Experimental Gerontology, 2018, Volume 112, Page 119
[2]
Diego Marcos-Pérez, María Sánchez-Flores, Ana Maseda, Laura Lorenzo-López, José C. Millán-Calenti, Barbara Strasser, Johanna M. Gostner, Dietmar Fuchs, Eduardo Pásaro, Vanessa Valdiglesias, and Blanca Laffon
Journal of the American Medical Directors Association, 2017
[3]
Marisa Möller, Leoné Malan, Martin Magnusson, Carina M. C. Mels, and Nico T. Malan
Psychophysiology, 2017, Volume 54, Number 5, Page 696
[4]
Lenka Kujovska Krcmova, Barbora Cervinkova, Dagmar Solichova, Lubos Sobotka, Lenka Hansmanova, Bohuslav Melichar, and Petr Solich
Bioanalysis, 2015, Volume 7, Number 21, Page 2751

Comments (0)

Please log in or register to comment.
Log in